Hyundai ADM Bio recently announced a name change to Penetrum Bioscience during its regular shareholder meeting on the 6th, marking a strategic shift aimed at clarifying its research and development focus around the new drug candidate 'Penetrum.' This rebranding aligns with the company's commitment to improving the oral drug formulation based on the existing anthelmintic compound, Niclosamide, which aims to enhance absorption rates in the body and provide a therapeutic approach to regulating cellular energy metabolism.

The company anticipates that Penetrum could evolve into a platform-type drug with potential applications in treating various intractable diseases such as cancer and autoimmune disorders. Ongoing clinical research includes studies for prostate cancer and late-stage patients with breast and lung cancer, as well as plans for international clinical research on rheumatoid arthritis, reflecting a robust pipeline for the newly branded enterprise.

Jowon Dong, the chairman of Penetrum Bioscience, emphasized the importance of understanding the pathological environments of intractable diseases from an energy metabolism perspective, suggesting that it could lead to a common therapeutic approach among different conditions. He indicated that whether Penetrum can develop into this new treatment paradigm will be determined through careful validation in future clinical trials.